Swiss Biotech Day: Zurich based LimmaTech Biologics is developing vaccines against antimicrobial resistant pathogens

blonca9
May 5
1 min read

CEO Franz-Werner Haas describes the rationale for developing vaccines for the antimicrobial space, he explains the company's E. coli based platform, and he walks us through the pipeline.

Recent Posts

See All

Cambridge, UK based Maxion Therapeutics raised a $72M series A in March to advance its KnotBody programs - which combine the benefits of knottins and antibodies and can target ion channels and GPCRs

ASGCT 2025: HuidaGene presented preclinical and early clinical data for its CRISPR Cas12 based program for DMD in a Presidential Symposium talk

ASGCT 2025: Dyno Therapeutics' CEO Eric Kelsic discusses the latest in capsids for CNS, ophthalmology, and neuromuscular conditions

Swiss Biotech Day: Zurich based LimmaTech Biologics is developing vaccines against antimicrobial resistant pathogens

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight